Immucell (ICCC) Free Cash Flow (2010 - 2025)

Immucell (ICCC) has reported Free Cash Flow for 16 consecutive years, with $310235.0 the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Free Cash Flow rose 255.69% year-over-year to $310235.0; the trailing twelve-month figure through Dec 2025 stood at $1.2 million (up 1236.0% YoY), and the FY2025 full-year result was $1.2 million, up 1236.0% from the prior year.
• Free Cash Flow advanced to $310235.0 in Q4 2025 per ICCC's latest filing, from -$1.8 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $1.4 million in Q2 2025 and bottomed at -$3.4 million in Q1 2023.
• Historically, Free Cash Flow has averaged -$631167.1 across 5 years, with a median of -$493120.5 in 2021.
• The sharpest annual moves came in 2022 and 2025: Free Cash Flow tumbled 2289.01% in 2022, then soared 257.54% in 2025.
• Over 5 years, Free Cash Flow stood at -$116701.0 in 2021, then sank by 2289.01% to -$2.8 million in 2022, then surged by 71.15% to -$804415.0 in 2023, then surged by 75.23% to -$199267.0 in 2024, then jumped by 255.69% to $310235.0 in 2025.
• According to Business Quant data, Free Cash Flow over the past three periods registered $310235.0, -$1.8 million, and $1.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.